Journal
JOURNAL OF CONTROLLED RELEASE
Volume 201, Issue -, Pages 90-99Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2015.01.026
Keywords
Nanoscale coordination polymers; Oxaliplatin; Gemcitabine; Synergistic effect; Pancreatic ductal adenocarcinoma
Funding
- National Cancer Institute [U01-CA151455, CA014599]
Ask authors/readers for more resources
Gemcitabine has long been the standard of care for treating pancreatic ductal adenocarcinoma(PDAC), despite its poor pharmacokinetics/ dynamics and rapid development of drug resistance. In this study, we have developed a novel nanoparticle platform based on nanoscale coordination polymer-1 (NCP-1) for simultaneous delivery of two chemotherapeutics, oxaliplatin and gemcitabine monophosphate (GMP), at 30 wt.% and 12 wt.% drug loadings, respectively. A strong synergistic therapeutic effect of oxaliplatin and GMP was observed in vitro against AsPc-1 and BxPc-3 pancreatic cancer cells. NCP-1 particles effectively avoid uptake by the mononuclear phagocyte system (MPS) in vivo with a long blood circulation half-life of 10.1 +/- 3.3 h, and potently inhibit tumor growth when compared to NCP particles carrying oxaliplatin or GMP alone. Our findings demonstrate NCP-1 as a novel nanocarrier for the co-delivery of two chemotherapeutics that have distinctive mechanisms of action to simultaneously disrupt multiple anticancer pathways with maximal therapeutic efficacy and minimal side effects. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available